Godavari Biorefineries Ltd received a patent grant from the Mexican Patent Office on October 2, 2026. The patent covers the use of specific compounds for treating viral infections by inhibiting V-ATPase activity in cells.

The invention details the use of these compounds in the manufacture of medicaments for viral infection treatment. This disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Patent Details and Validity

The Mexican Patent Office granted the patent titled "USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS" to Godavari Biorefineries Limited. The grant certificate confirms the ownership and scope of the intellectual property rights.

The patent is valid for twenty years, counted from the date of the international application filing. It expires on May 10, 2041, subject to the payment of maintenance fees as required by law.

Technical Scope and Inventors

The patent classifies the compounds under several International Patent Classification (IPC) and Cooperative Patent Classification (CPC) codes, including A61K31/4709 and A61K31/36. These classifications relate to medicinal preparations containing organic active ingredients.

The inventors listed in the patent are Maithili Athavale, Sandip Gavade, Prashant Kharkar, and Sangeeta Srivastava. The company holds the domicile at Somaiya Bhavan, Mumbai.

Regulatory Compliance

Godavari Biorefineries informed both the National Stock Exchange of India Limited and BSE Limited about this development. The company secretary and compliance officer, Manoj Jain, signed the disclosure letter digitally on October 2, 2026.

This grant adds to the company's portfolio of intellectual property assets in the biotechnology and pharmaceutical sectors. The patent was issued by the Instituto Mexicano de la Propiedad Industrial (IMPI).

Godavari Biorefineries Limited has disclosed the voting results for its Seventy-First Annual General Meeting held on September 28, 2026. Members approved all 10 resolutions put to vote, including the adoption of FY26 financial statements and several key director appointments.

The meeting was conducted via Video Conferencing and Other Audio-Visual Means (OAVM). A total of 91 members participated virtually, comprising 16 from the promoter group and 75 public shareholders. The proceedings were chaired by Samir Somaiya, Chairman and Managing Director.

Voting outcomes on key resolutions

While all resolutions were passed, the voting pattern revealed significant divergence among institutional investors regarding executive compensation. The resolution approving the re-appointment and remuneration of Samir S. Somaiya as Managing Director saw a notable split in votes.

What the numbers show

The voting data highlights a clear divide between promoter support and institutional sentiment. For the re-appointment of Samir S. Somaiya as Managing Director, Public Institutions voted 52.52% against the resolution, casting 26,79,619 votes against versus 24,22,277 in favour. This contrasts sharply with the near-unanimous support from Promoters (100%) and Public Non-Institutions (99.89%).

A similar pattern emerged for two other special business items: contribution to charitable funds and acceptance of deposits. In both cases, Public Institutions voted approximately 48.5% against the proposals. Despite this dissent, the high participation rate from promoters (who hold a majority stake) ensured the passage of all special resolutions, which require a 75% majority of votes cast.

Director appointment details

The company ratified the terms for four key directors. The table below outlines their backgrounds and appointment terms as approved during the meeting.

All directors confirmed they are not debarred from holding office by any SEBI order or other authority.

Meeting logistics and attendance

Remote e-voting commenced on September 25, 2026, and concluded on September 27, 2026. Tushar Shridharani of Tushar Shridharani and Associates LLP served as the scrutinizer for the electronic voting process. The scrutinizer's report confirmed that votes were unblocked after the conclusion of the AGM on September 28, 2026.

Key attendees included Executive Directors Dr. Sangeeta Srivastava, Bhalachandra Bakshi, and Suhas Godage. Independent Directors Nitin Mehta, Prof. Lakshmi Kantam, Hemant Luthra, Sean Reagan, and Nandan Mehta were also present. Naresh Khetan served as Chief Financial Officer.